A service of the U.S. National Library of Medicine
National Institutes of Health
For Uninfected Partner, Antiretroviral Drugs May Shield Against HIV
Study of heterosexual couples in Uganda suggests strict adherence to meds is key
URL of this page: http://www.nlm.nih.gov/medlineplus/news/fullstory_140532.html
(*this news item will not be available after 12/09/2013)
Tuesday, September 10, 2013
TUESDAY, Sept. 10 (HealthDay News) -- Antiretroviral drugs can provide a high level of protection against HIV for uninfected people in heterosexual couples in which the other partner has HIV, according to a new study.
The study included more than 1,100 HIV-uninfected people in Uganda who had a partner with HIV, the virus that causes AIDS. The participants were given antiretroviral drugs and received counseling support throughout the study to help them adhere to their drug regimen.
The drug adherence rate was 97 percent to 99 percent in the study, which was published Sept. 10 in the journal PLoS Medicine.
After an average follow-up period of 11 months, just 14 of the participants became infected with HIV, according to a journal news release.
The findings provide further proof that strict adherence to what is called antiretroviral pre-exposure prophylaxis offers high levels of protection to uninfected people, said Jessica Haberer, of Harvard Medical School, and colleagues.
The researchers said several previous studies in various groups (such as men who have sex with men, or women at high risk for HIV) have shown that taking antiretroviral drugs provided uninfected people with varying levels of protection against HIV. One possible explanation for the range of findings is different levels of adherence to the antiretroviral drugs, the researchers said.
"Proper support and assessment of adherence will be critical for determining efficacy of [pre-exposure prophylaxis] outside of clinical trials," the study authors wrote. "This data will be important for guiding ethical decisions about resource allocation for both prevention and treatment of HIV."
The Bill & Melinda Gates Foundation funded the study.
SOURCE: PLoS Medicine, news release, Sept. 10, 2013The study included more than 1,100 HIV-uninfected people in Uganda who had a partner with HIV, the virus that causes AIDS. The participants were given antiretroviral drugs and received counseling support throughout the study to help them adhere to their drug regimen.
The drug adherence rate was 97 percent to 99 percent in the study, which was published Sept. 10 in the journal PLoS Medicine.
After an average follow-up period of 11 months, just 14 of the participants became infected with HIV, according to a journal news release.
The findings provide further proof that strict adherence to what is called antiretroviral pre-exposure prophylaxis offers high levels of protection to uninfected people, said Jessica Haberer, of Harvard Medical School, and colleagues.
The researchers said several previous studies in various groups (such as men who have sex with men, or women at high risk for HIV) have shown that taking antiretroviral drugs provided uninfected people with varying levels of protection against HIV. One possible explanation for the range of findings is different levels of adherence to the antiretroviral drugs, the researchers said.
"Proper support and assessment of adherence will be critical for determining efficacy of [pre-exposure prophylaxis] outside of clinical trials," the study authors wrote. "This data will be important for guiding ethical decisions about resource allocation for both prevention and treatment of HIV."
The Bill & Melinda Gates Foundation funded the study.
HealthDay
Copyright (c) 2013 HealthDay. All rights reserved.
- More Health News on:
- HIV/AIDS Medicines
.png)
No hay comentarios:
Publicar un comentario